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Abstract Considerable research is aimed at determining
the mechanism by which tumor cures, or regrows or second
cancer develops, to be predictable and controllable. The
wide range of doses, from low to very high, estimated
statistically is responsible for such risks. A mathematical
model is presented that describes both: the growth due to
lower or over irradiated doses or the post therapy relapse of
human cancer, and the shrinkage due to either of over
irradiated doses, or appropriate irradiated doses. Simula-
tions of the presented model showed that the initial tumor
energy, administered dose energy, and their subsequent
summation of tumor regrowth energy are always balanced
with summation of Whole Body Cell Energy Burden
during all treatment phases. Tumor regrows if its energy is
higher than that of the dose, or if the increase of dose
energy from that of the tumor is less than the one required
to complete its shrinkage path. Patient-specific approaches
that account for variations in tumor energies should enable
more accurate dose estimates and, consequently, better
protection against either lower or over irradiation that
could lead to tumor regrowth and increase risks of second
cancer.
Keywords Curing time . Summation of tumor growth
energy .Whole Body Cell Energy Burden . Lower irradiated
dose treatment . Over irradiated dose treatment
1 Introduction
Since, the number of cancer survivors increases, prediction
of radiotherapy induced second cancer risks becomes a
considerable issue. The lifetime risk of radiation-induced
second cancers in these subjects can’t be neglected
(Brenner et al. 2007), and these second cancers can result
in morbidity or high death rates. For instance, it is evident
that breast cancer radiotherapy can cause lung cancer
(Brenner et al. 2000; Ron 2006), and secondary rectal
cancer rates are higher in prostate cancer patients (Harlan et
al. 2001a). Consequently, second malignancies induced by
radiotherapy are becoming a growing concern such that
radiation is considered a potential cause of cancer but, at
the same time, this risk is greatly outweighed by the
reduction in risk that occurred due to treating the original
tumor (Schneider and Besserer 2010). Many studies dealing
specifically with some related problems like relapsed cases
have conducted such risks, but most of them have not
introduced a conceptual reasoning to this issue for its
statistical analysis nature, or could not show how to predict
the time necessary for either curing or regrow. Yet, none of
these latter-day scientists could propose a theory or a
concept for the mechanism of the treatment kinematics of
such an unlikely appearing event as the curing or regrowth
time of radiotherapy treatment. Strategy of cancer treat-
ments is to include all cancer phases: phase I prior to the
treatment, to phase II during it and to phase III afterwards.
Phase I clinical trials are conducted to find recommended
doses, where toxicity of the agent is typically assessed to
determine what dose is appropriate for subsequent trials.
Since, the statistical power of phase I drug trials is
inadequate to assess antitumor efficacy, currently, Emad
Moawad presents a promising physical power approach of
phase I, contributing to the safest and low cost successful
E. Y. Moawad
Department of Engineering, Ain Shams University,
Cairo, Egypt
E. Y. Moawad (*)
217 Alhegaz Street, App.14, Alnozha,
11351, Cairo, Egypt
e-mail: emadmoawad@hotmail.com
Cancer Nano (2011) 2:81–93
DOI 10.1007/s12645-011-0018-4
treatment. It linked the radiobiology associated with dose
delivery and viewed dose from a purely physical model of
energy deposition (Moawad 2010). The equation of such an
approach that can be applied for all types of radio therapies
is as follows:





 13111lnE131IEmadln131 ¼ 23234:59MeV; ð1:2Þ
A0 & G0 are the initial activities of each of administered
doses and the tumor, respectively, QIso is the used isotope
decay energy, t1/2&tD are the half-life time of the used
radionuclide and the tumor doubling time, respectively,
while ECell&h% are the tumor cell growth energy in Emad
and the percentage of the hypoxic cells, respectively
(Gillies and Gatenby 2007; Sullivan and Graham 2007;
Brown 1999). Knowing that a tumor of 1 g converted into
109 ng contains 109 cells, it would be more convenient to
express the tumor cell growth energy by nanoscale as
equivalent to the growth energy of a tumor of 1 ng or one
nanoparticle investigating whether we can directly control
matter on the molecular scale. Hereby, in all sections of the
current approach the nanoparticle will be expressed by the
cell itself (Ecell = Eng), i.e.,
A0  QIso  t1 2= ¼ G0  ETumor:of :1:ng  h% 23234:59
  tD
ð1:3Þ
This relation enables us to test all the background of
medical dosimetry experiments that, based on the statistical
analysis as well as prior successful treatments, had been
conducted in different schools of medicine. In an effort to
assist in the understanding of recurrent cancer and the
energy balance processes that mediate this disease, this
approach provides a framework for using mathematical
techniques to study novel therapeutic strategies aimed at
controlling this disease and tries to relate the cancer
therapeutic drugs course of phase I prior the treatment to
tumor response of phases II and III.
2 Methods and materials
2.1 Mathematical model
A mathematical investigation of the multiple pathways to
recurrent cancer is covered: there are two reasons for tumor
regrowth; these reasons are either underestimation or
overestimation of the administered dose. The curves of
energies of treated tumors by either of Lower Irradiated
Dose Treatments LIDT or Over Irradiated Dose Treatment
OIDT would have different attitudes for each case. An
important aspect of the model is that tumor size may vary
during treatment; if rate of growth is faster than that of cell
killing, the tumor volume will increase. Conversely, if rate
of cell killing is faster than that of the growth, the tumor
volume decreases. The tested hypothesis of the current
mathematical model is that summation of tumor growth




from the balance between initial tumor energy E0.Tumor,
initial drug energy E0.Doses, and, finally, amount of energy
that the whole body disposed of by rate of radionuclide
decay constant within the same duration, which is known
by summation of Whole Body Cell Energy Burden
∑WBCEB, such that:
X





Provided that the way of whole body self adaptation,
according to the whole-culture measurement approach point
of view, is that radiation effects propagate gradually by
radionuclide decay constant circularly from internal nano-
particles (cells) to be released in the neighborhood and so on
till the outer nanoparticles (cells) and then to the surrounding
environment. This recovery operation lasts till Whole Body
Cell Energy Burden (WBCEB) for all body nanoparticles
(cells) reaches the Natural Background Radiation (NBR) level
settled by the Committee on the Biological Effects of Ionizing
Radiations (BEIR) of the National Research Council, and
shown by Emad Moawad that it is equivalent to (ENBR =
0.0000538132 Emad) (Moawad 2011). Thus, all body
nanoparticles (cells) were involved in recovery burden, and
then ∑WBCEB = the Whole Body Cell Energy Burden
(WBCEB) gained due to radiotherapy × C0 (the total number
of the body nanoparticles (cells)). Negative or positive sign
(∓) to cover all types of treatments with respect to dose
energy, negative for either of the Over Irradiated Dose
Treatment OIDT or treatments that follow work–energy
principle WEPT (Moawad 2010), and positive for the Lower
Irradiated Dose Treatment LIDT. The main features and
assumptions of the mathematical model describing the
response of the tumor to radiotherapy are as follows: the
tumor is viewed as a densely packed, radially symmetric
sphere. Cell movement is produced by the local volume
changes that accompany cell proliferation and death. The
spheroid expands or shrinks at a rate that depends on the
balance between cell growth and division and cell death
within the tumor volume (O’Donoghue 1997). Controlled
tumors follow a growth curve by an exponential function of
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growth constant equivalent to ln2/tD, where tD is the tumor
doubling time; the initial tumor cell energy can be
determined by Emad’s formula (Emad 2010):
ETumor:of :1ng ¼ ETumor:Cell ¼ ln ln ln2tD
 2" #
ð2:1:2Þ
According to the work–energy principle, the accuracy of
estimating the initial effective radioactive dose depends on
the equivalence of the initial growth energy of the tumor
and the initial decay energy of the effective radioactive dose
(Moawad 2010), i.e.,
E0:WEPT ¼ E0:Tumor ð2:1:3Þ
Such Work–Energy Principle Treatment WEPT posits
that the tumor will be cured such that the tumor shrinkage
constant will be identical to the decay constant of the used
radionuclide. This means that in such a case, the value of
the used radionuclide half-life time will be an approximate
value for the half-time of doomed cell loss:
t1=2Shrinkage ¼ t1=2Isotope; ð2:1:4Þ
i.e., the treated tumor according to WEP will be cured and
shrunken exponentially by the decay constant of the used
radioactive dose. This provides a hypothesis that curves of
energies of each of the treated tumor according to WEP, and
the radioactive dose as functions of time are congruent
along the whole treatment. This means that energy of the
tumor ETumor along the WEPT is




Accordingly, the ratio of the dose released energy during a




ET in the same duration is equivalent to
the radionuclide decay constant, i.e.,
XT
t¼o








Such a hypothesis can be tested by integrating the
function of the tumor energy pathway along the studied
duration. In addition, this approach posits that in case of
WEPT treatments, the time passed for the WBCEB under a




to reach the ENBR is the curing
duration. Then, in such a case, from Eq. (2.1.1), summation
of Whole Body Cell Energy Burden is equivalent to the
sum of energies of each of the dose and the tumor, i.e.,X
WBCEB¼E0:DoseþE0:Tumor ð2:1:7Þ
)WBCEB ¼ E0:Tumor þ E0:Dose
C0:Whole:Body
ð2:1:8Þ
since E0.Tumor = E0.Dose in WEPT as shown in Eq. (2.1.3),
then WBCEB ¼ 2E0:DoseC0:Whole:Body . Such curing time should be
minimized as much as possible to reduce serious normal
tissues toxicities (Schneider and Besserer 2010). Therefore,
radionuclides with short half-lives offer advantages over
those with longer lives; advantages over existing techniques
include extremely low radiation dose because of the short
half-life of the isotope ease. After passing n radionuclide
half-life times the WBCEB will be decreased to the ENBR.
Accordingly, ENBR Cellð Þ ¼ WBCEB2n ¼ 2E0:Dose2nC0:Whole:Body , and then
curing time of the radiotherapy treatments is:









The significance of the above relation shows the
possibility to decrease time of both of phase II and phase
III in which the treated body disposes dose and tumor
energies and comes back to ENBR or in other words:
disposes tumor and drug toxicities to decrease the risks for
inducing second cancer (Schneider and Besserer 2010). The
remission duration is taken as the time between the start of
treatment and tumor regrowth to some size or cell number
threshold (O’Donoghue 1997). In either of LIDT or OIDT,
summation of WBCEB will be decreased by energy
consumed for regrowth, and then from Eqs. (2.1.7) and
(2.1.1)X





Also, for time of tumor regrowth from Eq. (2.1.9)
TGrowth ¼ t1 2=  log2






This equation is not applicable for tumor regrow time
prediction as ∑ETumor.Growth must be known first, but it
contributes to prove that the energy balances during
radiotherapies for all types of tumor responses in accor-
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dance to the given experimental data. In addition, the
physical quantity, ∑WBCEB, introduced in the presented
mathematical model can be calculated according to the
whole body measurement approach point of view, by
considering that whole body cells gain energy after
exposure to radiation, which leads to the increase of their
growth energy exponentially by the growth constant of used
radionuclide. Accordingly, if a healthy subject has been
exposed to radiation dose for a certain duration (T), then














In LIDT, in the absence of energy equilibrium between
initial tumor energy, E0.Tumor, and that of administered dose,
ELIDT, tumor growth will be the resultant of the activated
nuclear transmutations, as shown by Emad Moawad
(2010); LIDT curve would be grown to a level of tumor
energy equivalent to
ETumor ¼ E0:Tumor þΔEDoses; ð2:1:13Þ
where ΔEDoses is the difference between the initial tumor
energy and that of insufficient dose administered in LIDT, i.e.,
) ETumor ¼ E0:Tumor þ E0:Tumor  ELIDTð Þ. In addition, sum-








postulated in Eq. (2.1.1). Then, from Eq. (2.1.12)
XT
T¼0




and can be checked through integrating the area shown in
Fig. 1 between tumor energy curve of LIDT and that of the
initial energy level. While for OIDT compared to WEPT in
case of tumor shrinkage, the difference between their
released energies would be equivalent to the summation of




) E0:OIDT  E0:WEPT ¼
X
ETumor:WEPT  ETumor:OIDTð Þ:
ð2:1:15Þ
To test the previous hypothesis, the tumor energy
progression should be determined along the whole treat-
ment for OIDT and WEPT. The accumulated difference of
the tumor energies along both treatments, which is the sum
of difference of energies of the faster shrunken than the
slower one, should be equivalent to the accumulated
difference of energy of the administered doses in both
treatments, i.e.,
















The different tumor responses along treatments of
different dose energies with respect to that of the tumor
are represented graphically in Figs. 1 and 2.
For OIDT, curve of tumor response energy would be
compressed, following a higher decay constant than that of the
used radionuclide, of half-life time t1/2.Shrinkage > t1/2.Isotope,
leading to faster shrinking than that of the WEPT as shown in
Figs. 1 and 2, i.e.,





At the same time, this model enables to predict the
shrinkage half-life time during a certain time T in either
WEPT or OIDT according to the following equation:
t1 2Shrinkage= ¼ 2
n








where E0.OIDT ≥ E0.Tumor. Hence, by trial and error method,
assuming values of n satisfies











then Eq. (2.1.17) can be simplified for long-term radiother-




Moreover, Eq. (2.1.17) shows that for WEPT: E0:Tumor ¼
Different Tumor responses 















Fig. 1 Different tumor responses in LIDT and WEPT and OIDT
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E0:WEPT ) t1 2Shrinkage= ¼ t1 2Isotope= as postulated for the
presented mathematical model. This fast shrinkage will
last, under the condition that the difference of the total
decay energies that are released from both treatments,
OIDT and WEPT, is higher than the accumulated difference
of the tumor energies along both treatments, i.e.,
$EDoses 
P
$ETumor:Shrinkage, as shown in Fig. 2. Once
these differences become close to each other, as the
shrinkage slows gradually to the minimum tumor size of
OIDT, and then reverses its response, regrows to achieve
the balance with that of WEPT according to its time course
when $EDoses ¼
P
$ETumor:Shrinkage. Afterwards, the tumor
energy curve of the OIDT will continue to regrow
negatively above that of the WEPT as shown in Fig. 2 to
a level of energy such that this accumulated tumor response







WBCEB as previously postulated for the math-
ematical model in Eq. (2.1.1); from Eq. (2.1.12)
XT
T¼0




which can be checked through integrating the area shown in
Fig. 2 between the tumor energy curve of OIDT and that of
WEPT starting from their intersection.
2.2 Lower irradiated dose treatment
This application shows that tumors under LIDT will grow or
gain energy equivalent to the difference in energy of WEPT
from that of LIDT, i.e., ETumor ¼ E0:Tumor þ ΔEDoses,
ΔEDoses ¼ EWEPT  ELIDT as shown in Eq. (2.1.13). Fur-
thermore, it tests the hypothesis of the LIDT mathematical
model
P
ETumor:Growth ¼ E0:Tumor þ E0:Doseð Þ þ
P
WBCEBj j
as shown in Eq. (2.1.1). Thakur et al. (2003) showed
methods and materials for experiments in nude mice bearing
human tumors: approximately 5×106 viable human prostate
(DU145), breast (T47D), or colorectal cancer (LS174T) cells
were implanted into nude mice in groups of ten mice each,
and tumors were allowed to grow to (0.61 cm in diameter)
5×108 ng and treated with 16.7 MBq (450 μCi). 111In-oxine
grew, on the average, only 17% irrespective of their type—
breast, prostate, or colorectal, within 28 days after injection
(Thakur and Ron Coss 2003), while those treated by
18.5 MBq (500 μCi) did not grow within the same duration
as shown in Figs. 3 and 4.
To test whether the lower administered dose (16.7 MBq
of 111In) was appropriate or not, the tumor cell growth
energy, E0.Cell, and its doubling time, tD, which is adequate
for such a dose can be derived from the equations
E0:ng ¼ E0:Cell ¼ N0:Iso  QIso
m0  109  h% Emad131I
Emad;





(Moawad 2010), which show that this dose was appropriate
for tumor cell (nanoparticle of 1 ng) growth energy
equivalent to Eo.Cell=Eo.ng=4.385 Emad, corresponding to
tumor doubling time, tD=5384.51 s=0.06 days, while the
presented data shows that tD was equivalent to 28 days.
This great difference in dose energy supply from that of the
tumor allows tumor growth through the phenomenon of
transmutation that permits transformation of elements in
live organisms [9 s]. For growth calculations, Emad
Moawad explained (2010) that those little doses were not
sufficient. The growth energy of the untreated (controlled)
tumor was 1.0091 J, while the decay energy of the
insufficient dose from In-111=0.816 J only. Tumor growth
energy (17%) + dose decay energy (insufficient dose) =
0.1717+0.8161=0.988 J, which achieves an accuracy of
98% of the growth energy of the untreated (control) tumor
(1.0091 J). In addition, $EDoses ¼ 1:0091J 0:816J ¼
0:1931J. At the same time, the regrowth energy,ΔERegrowth,






















Fig. 3 Monitoring tumor responses for different doses [none,
16.7 MBq and 18.5 MBq] (Thakur and Ron Coss 2003)















Fig. 2 Tumor response in OIDT led to tumor regrowth
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was 17% 1:0091J ¼ 0:1717J, following a doubling time
of 123.6156238 days. This indicates that the tumor
regrowth energy due to LIDT is less than the difference
between WEPT and LIDT dose energy. To check the
hypothesis of the mathematical model: summation of tumor
growth energy,
P
ETumor:growth, can be calculated along time
of growth 28 days as presented in the experimental data as
follows: from Eq. (2.1.1 & 2.1.14)
XT
T¼0
ETumor:Response ¼ 0:81612302þ 1:0091þ 25 108  0:0000538132 23234:59
6:242 1012  2
2824
67:9 ¼ 2:303 J:
Tshis value can be reached by integrating the presented












as shown in Fig. 3 (Fu et al. 2004). This is nearly 100%
identical to the experimental data that presented by Thakur
et al.’s measurement (2003). In addition, from Eq.
(2.1.17), if the administered dose would be 20.66 MBq
(1.0091 J), as shown by Emad Moawad, instead of the
applied ones (16.7 MBq, 18.5 MBq) by Thakur et al. to
satisfy the WEPT, the shrinkage half-life time is supposed
to be
t1 2Shrinkage= ¼ 2
n















by trial and error method. The value of n that satisfies Eq.
(2.1.18) is n=9.9 as it gives t1/2.Shrinkage equivalent to









2:83tdt ¼ 4:1 J
along 28 days as shown in Fig. 4 (Brown 1999); this is
also nearly 100% identical to the ratio of the dose
released energy during the same period by the decay
constant of the radionuclide, as previously postulated for
the features of the mathematical model in Eq. (2.1.6)





 t1 2:Isotope= ln 2 ¼ 1:0091
1 e  ln 267:9 2428ð Þ
h i
 67:924ln 2 ¼ 4:11 J.
2.3 Over irradiated dose treatment
O’Donoghue et al. (2000) showed the temporal behavior of
a surviving fraction for a tumor of (1×1011 ng) initial mass
with the baseline response parameters. The tD of the tumor
cells was taken as 4 days. This represents a central estimate
of values measured by bromodeoxyuridine labeling in
human tumors (Terry et al. 1995; Tsang et al. 1995; Bolger
et al. 1996; Bourhis et al. 1996). The single, large
administrations of LSA treatment consists of an adminis-
tration of 8.25 GBq (223 mCi). A value of 3 days was used
as an approximate value for the half-time of doomed cell
loss (Ts). The time courses of tumor regression and
recurrence for the treatment showed that the minimum
tumor size reached was (7.2×108 ng) at 27.6 days for LSA.
If remission duration is defined as the time to regrow to a
tumor mass of (5×109 ng), then this was 53.2 days counted
from the start of dose delivery (O’Donoghue et al. 2000);
these experimental data are shown in Fig. 5.
Checking the thesis of this approach and mathemat-
ical model accuracy:knowing that tD=4 days, from Eq.
(2.1.13), the growth energy of tumor nanoparticle (cell),
























Fig. 4 Calculations of the
tumor groups [controlled,
relapsed and cured] responses
over 28 days (Moawad 2010)
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Eng ¼ ECell ¼ ln ln ln 24 24 60 60
 2" #
Emad:
Then, the total tumor growth energy
E0Tumor ¼ C0  h% ECell  Emad131I
6:242 1012 J
¼ massng  h% Eng  Emad131I
6:242 1012 J;
) E0Tumor ¼
1 1011ng  10%
6:242 1012
 ln ln ln2




While the administered dose was 8.25 GBq, of decay
energy.
E0:Dose ¼ 8:25 10
9Bq 8:04d 24h 60min 60sec  0:97MeV
ln2 6:242 1012MeV=J
¼ 1284:837 J;
which is obvious much more than E0.Tumor representing
an OIDT, as from the point of view of this approach the
initial decay energy of the administered dose was
supposed to be 192.065 J, instead of 1284.837 J, and all
such energy difference (1092.772 J) is considered an over
irradiated dose, responsible for the consequent tumor
regrowth. During this treatment, the initial tumor size
shrunk, and the time courses of tumor regression and
recurrence for the treatment showed that the minimum
tumor size reached was 7.2×108 ng at 27.6 days. The
corresponding half-life time of tumor decay was
3.87761 days. The first hypothesis of the OIDT mathe-
matical model in which the accumulated difference of the
tumor energy along OIDT from that of WEPT will be
equivalent to the accumulated difference of energy of the















A ¼ E0:D  E0:T
as shown in Eq. (2.1.16) can be tested as follows: the
tumor energy progression should be determined along the
whole treatment for both administrations, OIDT and
WEPT. The accumulated difference of the tumor energies
along both treatments, which is the sum of the difference
of energies of the occasional faster shrinkage than the
slower one, and the consequent regrow, should be
equivalent to the accumulated difference of the energy of
the administered doses in the same interval from treatment
start until equivalence of tumor energies in either
treatment, i.e., until their curve intersection (balancing
point). Firstly, from t=0 to t=27.6 days, the stage of the
fast shrinkage, size of the over irradiated tumor decreased
faster than the size of the one irradiated according to WEP,
due to the over irradiated dose, the difference between its
decay energy, and the decay energy administered by WEP
released within this interval, ΔEDoses, where




Whi le the accumula t ed ene rgy d i f f e rences

























Secondly, from t=27.6 days to t=53.2 days, the time
courses of the over irradiated treatment showed that the
tumor size regrow from 7.2×108 ng and reached 5×109 ng.






















Fig. 5 Tumor response in both
of OIDT and WEPT
Radiotherapy and risks of tumor regrowth… 87
9.1564 days. The WEP treatment showed that the tumor
size decayed exponentially following the decay constant
of the used radionuclide. Consequently, the time courses
of both treatments showed that tumor energy would
get the same energy in both treatments after their
start by 43.419 days. At this balancing point, the
accumulated differences between tumor energies along



















9:156tdt ¼ 111:616 J:
ð2:3:2Þ










¼ 954:77þ 111:616 ¼ 1066:39J
ð2:3:3Þ
as shown in Fig. 5. While the difference of the released
energy between the over irradiated dose and the WEP one is
$EDoses ¼ 1284:837J 192:065Jð Þ




From Eqs. (2.3.3) and (2.3.4), it can be deduced that in the
same period, from t=0 to t=43.419 days, the difference
between the decay energy of the over irradiated dose and that
administered by the WEP that was released within this
interval, ΔEDoses, is equivalent to the accumulated differ-





ΔETumor:Shrinkage, along the same period [from
start till balancing point] as previously postulated by Eq.
(2.1.15). To check the second hypothesis of the OIDT
mathematical model: summation of tumor growth energy,P
ETumor:growth, can be calculated along the time of growth,
53.2 days, as shown by O’Donoghue et al. as follows: from
Eqs. (2.1.1) and (2.1.19)
XT
T¼0
ETumor:Regrow ¼ 1284:8þ 192:065 70 1012
 0:0000538132 23234:59
6:242 1012  2
53:2
8:04 ¼ 100:6 J
This value can be reached by integrating the presented




















as shown in Fig. 5. This is nearly 100% identical to the
experimental data that was presented by O’Donoghue et
al.’s measurement (2000). This test can be executed
conversely; by knowing
P
ETumor:Regrowth, duration of such
tumor response can be determined from Eq. (2.1.11) as
follows:
TRegrow ¼ 8:04d log2
1284:837Jþ 192:065J 100:22Jj j  6:242 1012MeV=J




as previously presented in the experimental data. This success in
determining
P
ETumor:Growth enables us to predict whether
tumor will regrow or be cured after a certain time due to cancer
treatment. In addition, to check the third hypothesis of OIDT
mathematical model for fast shrinkage rate, the shrinkage half-
life time can be predicted from Eq. (2.1.17) as follows:
t1 2Shrinkage= ¼ 2
n










2n  1  3:716974;
by trial and error method. The value of n that satisfies Eq.
(2.17) is n=4.6 as it gives t1/2.Shrinkage equivalent to 3.877 days,
which is also 100% identical to O’Donoghue et al.’s
presentation (2000). As the goal of our model development
is second cancer risk prevention, this approach, hereby
suggests that WBCEB should be less than the Low Dose
Radiation (LDR) effect that was settled by BEIR and that was
shown by Emad Moawad to be equivalent to ELDR =
0.000538132 Emad or 12.503 MeV or 2.0030088×10−12 J
(Moawad 2011). In application 2.3-, ∑WBCEB has been
increased from (2 × 192.065) ×C0 J in WEPT to
2 192:065þ 1130ð Þ  C0 J in OIDT; this led to prolonga-
tion of the curing time shown in Eqs. (2.1.8) and (2.1.9) from
38.39 days in WEPT to 54.3 days in OIDT that could lead to
serious normal tissue toxicities and contribute in increasing
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second cancer risks. Therefore, OIDT is also considered one
cause of second cancer.
2.4 Estimating the WEPT from the tumor response
through the LIDT or the OIDT
This application for checking the efficacy of radiotherapies
after their execution helps in preserving patients’ rights
against the randomized statistical dose assessment that
ignores patient-specific factors. It shows that as the tumor
sizes and their doubling time in patients variedwidely, as these
differences produced significant differences between doses
assessed physically even for the same sizes (Rajendran et al.
2004). Barendswaard et al. (Barendswaard et al. 2001)
showed that 4- to 6-week-old athymic female Swiss
(nu/nu) mice, body weight 20 25 109ng, from their
in-house nude mouse facility were injected with 10×106
SW1222 cells in the left thigh muscle. After 5–7 days,
mice bearing tumors of 1.40–9.0×108 ng were selected. A
total of 169 mice were divided into groups of 4–9 mice.
Fourteen groups were administered varying amounts of
mAb A33 labeled with 131I. The activities of 131I-A33
ranged from 0.925 to 18.5 MBq (0.025–0.5 mCi). Tumor
size was measured bidimensionally with calipers, and the
volume was calculated assuming elliptic geometry. Initial
tumor sizes were between 0.14 and 0.90 cm3 (mean,
0.44 cm3), i.e., initial tumor masses were between 1.4 and
9.0×108 ng, mean 4.4×108 ng. Mice with tumors of
differing sizes were divided into groups such that the
tumor size spectrum for each group was similar. The
tumors were measured every 3 or 4 days for 100 days or
until the death of the animal. Mice were killed when the
tumor caused apparent discomfort in walking or when its
volume exceeded 2 cm3, i.e., when tumor mass exceeded
2×109 ng. Observations showed that tumor growth was
retarded after treatment to an extent that was dependent on
the amount of activity administered. Barendswaard et al.
showed that “tumors were considered cured if they failed
to regrow over the period of observation (100 d after
treatment), while occasional tumor cures were seen at
intermediate administered activities of 131I (3.7–
11.1 MBq), but a higher value (14.8 sMBq) did not
produce any cures. Four of five tumors in this group
became temporarily undetectable but subsequently re-
curred between day 40 and day 80. The highest activity
of 131I administered (18.5 MBq) resulted in tumor cures
in all four animals in that group.” (Barendswaard et al.
2001). Barendswaard et al. showed that the maximum
tolerated activities of 131I were 18.5 MBq (0.5 mCi) in
this model system. Activities of 18.5 MBq 131I caused
petechiae, which became apparent after 2 days and
confluent after 4 days; these activities also caused
progressive weight loss. Median tumor volume, normal-
ized to initial volume, as a function of time in nude mice
bore SW1222 xenografts when treated and shown in Fig. 6
as presented by Barendswaard et al. (2001).
Checking the postulates of this approach:
First: from tumor response of the controlled group, the
tumor doubling time was 4 days; consequently, from Eq.
(2.1.2) the cell (nanogram or nanoparticle) growth energy
was
Eng ¼ ECell ¼ ln ln ln24 24 60 60
 2
¼ 5:14 Emad ð2:4:1Þ
Second: as the initial tumor size was not provided by
Barendswaard et al., numerical simulations of Eq. (2.1.16)
can be applied to investigate the tumor’s initial size, which
can be estimated from the thesis of the equivalence of the
difference between areas under the curves of tumor
response during WEPT and OIDT and the difference















A ¼ E0:D  E0:T
as shown in Eq. (2.1.16). Then, by substituting data of this
experiment, shown by Barendswaard et al. (2001) (shrink-
age half-life time was 6.5 days along 20 days, for
18.5 MBq initial dose activity of 131I that corresponds to
2.881 J) in Eq. (2.1.16), calculation of the initial tumor
energy shows that
E0:T ¼ 1:2721 J; ð2:4:2Þ
that corresponds to 8.168 MBq only. This means that the
administered dose of WEPT was supposed to be
8.168 MBq; consequently, the doses of 14.8 MBq and
18.5 MBq are considered OIDT.
m0 ¼ E0TP
E0:HypoxicCell=ng
  ¼ 1:2721 6:242 1012


























Fig. 6 Tumor response due to different doses
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which is accepted as amedian value for the set of treated tumors
ranged (1.4–9.0)×108 ng, with a mean of 4.4×108 ng, as
given by Barendswaard et al. (2001).
Forth: a dose–response relationship has been studied for
the different administered doses. The highest activity of
131I administered (18.5 MBq) resulted in tumor cures in all
animals, but the value of 14.8 MBq did not produce any
cures and tumor regrowth was between day 40 and day 80.
The tumor response after dose delivery followed an
exponential shrinkage of half-life time of 6.5 days, contin-
ued only for the tumor that was assigned to the 18.5 MBq
of 131I dose, and cured. On the contrary, the tumor that has
been assigned to a dose of 14.8 MBq reached its minimum
size after 40 days; afterwards, it relapsed, following an
exponential growth of 14.46 days doubling time, and
reached a relative tumor size of 6.8 with respect to the
minimum size after 80 days from the dose delivery. To
check the hypothesis of OIDT mathematical model for fast
shrinkage rate of the 14.8 MBq (2.305 J) dose, the
shrinkage half-life time can be predicted from Eq. (2.1.17)
as follows:
t1 2Shrinkage= ¼ 2
n









2n  1  7:239463111
by trial and error method. The value of n that satisfies Eq.
(2.1.18) is n=5.5 as it gives t1/2.Shrinkage equivalent to
7.4 days. This rate causes the tumor energy to decrease
from 1.2721 J to 0.028 J after 40 days as
1:2721 e ln 27:4 40 ¼ 0:028 J:
Consequently, summation of tumor growth energy,P
ETumor:growth, can be reached by integrating the presented



















as shown in Fig. 6. The postulate of the provided mathematical
model summation of tumor growth energy,
P
ETumor:growth,
can be calculated by determining the required time of
regrowth as follows: from Eq. (2.1.1 & 2.1.19)
XT
T¼0
ETumor:Regrow ¼ 2:305þ 1:2721 25 108
 0:0000538132 23234:59
6:242 1012  2
80
8:04 ¼ 3:08 J:




ETumor:Regrow is the resultant of tumor and
dose energies against ∑WBCEB.
Fifth: to check the hypothesis of OIDT mathematical
model for fast shrinkage rate, also for the 18.5 MBq
(2.88 J) dose, the shrinkage half-life time can be predicted
from Eq. (2.1.17) as follows:
t1 2Shrinkage= ¼ 2
n









2n  1  5:8865
by trial and error method. The value of n that satisfies Eq.
(2.1.18) is n=3 as it gives t1/2.Shrinkage equivalent to
6.72 days, which is also 97% identical to Barendswaard et
al.’s presentation (6.5 days) (2001).
3 Results
Numerical simulations of Eqs. (2.1.1)–(2.1.19) are per-
formed to investigate the tumor’s response to radiotherapy
for various parameter values. The fit of the mathematical
model to the experimental data [2.2-, 2.3-, 2.4-] is based on
the tumor’s response to radiotherapy according to the
balance of the dose released energy and the summation of
tumor energy. During shrinkage stage, these energies are in
equilibrium, and once balance is violated, tumor will be




ETumor:Growth, results from the balance between
initial tumor energy E0.Tumor, initial drug energy E0.Doses,
and, finally, summation of Whole Body Cell Energy Burden
∑WBCEB, such that
P
ETumor:Growth ¼ E0:Tumor þ E0:Doseð ÞjP
WBCEBj. Negative or positive sign (∓) to cover all types
of treatments with respect to dose energy: negative for the
OIDT and positive for the LIDT. Despite OIDT may cure the
primary tumor in certain cases as shown in 2.4- for the higher
dose (18.5 MBq), it contributes in increasing WBCEB to
levels higher than that tolerated. The best fit of the model to
the experimental data allows for the estimation of the cure or
the regrowth at both low and high radiation doses to be used
for optimization of radiotherapy protocols.
3.1 Effects of changing model parameters
The stability of the conclusions of the modeling study was
investigated by varying the radiobiologic and pharmacokinetic
parameters associated with tumor response. The effects on
tumor response of varying the radiobiologic parameters lower
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and over the initial tumor energy were covered. In all cases,
cure responses were for WEPT and OIDT, which satisfied the
model energy balances of Eq. (2.1.7), whereas remission
responses were similar for all LIDT and OIDT that satisfied
Eq. (2.1.1). This was done for both macroscopic and
microscopic tumors. It should be noted that the tumor
response model is applicable for all kinds of cancer radio-
therapies. All variations of radiobiologic factors are explained
in only four parameters (a) initial tumor energy, (b) initial dose
energy, (c) summation of Whole Body Cell Energy Burden
and (d) summation of tumor energy, which arises as a result of
the unbalance between the sums of the first two parameters
against the third one. The possibility of adaptation of
shrinkage pathway is considered by changing the parameter
of the drug released energy to maintain the equation of energy
balances of this model. Notice that when ΔEDoses→0, which
represents the amount by which the dose energy differs from
that of WEPT, its resultant which is the difference in the
summation of tumor energy of either OIDT or LIDT from that
of WEPT
P
ΔETumor:Shrinkage ! 0 too, which is the optimal
targeted cancer radiotherapy. Moreover, the model relates all
types of tumor response to the difference between energies of
OIDT or LIDT from that of WEPT, with the capability to
predict the tumor pathway. This was done to keep the number
of model parameters at a minimum, but at same time, this
simulation shows that the model and so the tumor responses
are completely controlled by energy balances. In addition, it is
clear that there are specific times for which tumor response
energy exceeds the difference of OIDT energy from that of
WEPT, resulting in net growth. Further information regarding
interval time of the tumor response, whether cure or regrowth,
can be derived on the basis of the n half-life times needed for
WBCEB to reach the NBR. During the regrowth period, the
curve of tumor energy of OIDT surpasses that of WEPT
resulting in a balance point at which the model predicts the
level of tumor energy that can be reached above the curve of
tumor energy of WEPT. The model also predicts that tumor
relapse is associated with a decrease in released dose energy
from the supposed quantity needed to allow the tumor to
continue its shrinkage pathway.
4 Discussion
This article describes the application of a mathematical
model of tumor response to radiotherapy. The model is used
to examine energy balances that influence the therapeutic
effects of alternative administration patterns. Despite this, it
is easier to make administering doses simple and straight-
forward. It should be performed specific to patient and,
further, specific to normal organs or tissues at the greatest
risk for life-threatening tissue damage. As the tumor sizes
vary widely, individualized patient doses are supposed to
have a wide range, too. Significant differences produced
between doses are assumed statistically [standard masses]
and physically [individualized patient]. Since the issue of
radiotherapy-related second cancers will become increas-
ingly significant (Gold et al. 2003; Tubiana 2009), the aim
of the current approach is to relate the consequence of late
normal tissue damage from OIDT to a precancerous lesion.
Accordingly, preventing serious toxicities to normal vital
organs is not only essential but also perhaps, the ethical
responsibility of all involved in treating cancer patients as a
whole to ensure that these risks are made as low as possible
with improved understanding of the dose–risk relationship
at high doses (Sachs and Brenner 2005), with improved
dose delivery technology (Miralbell et al. 2002; Balog et al.
2005; Fu et al. 2004), and with more optimized treatment
planning (Mohan et al. 2000; Crooks et al. 2002; Coselmon
et al. 2005): as radiation administered dose estimation
techniques for internal radiation emitters continue to evolve
(Stabin 1999), as shown for WEPT (Moawad 2010),
accurate measurement of the uptake and retention of the
radiopharmaceuticals in organs and tissues is challenging,
but a reasonably accurate assessment of radionuclide
pharmacokinetics is feasible with current imaging techni-
ques (Rajendran et al. 2004). A cancer induction model for
radiotherapy was used to investigate the impact of different
dose energy patterns on second cancer risk. It allows
controlling tumor shrinkage pathway as it is recommended
to keep the shrinkage pathway congruent to that of
radionuclide decay energy as described in WEPT. This
means that it is not favorable for the tumor shrinkage
constant to exceed the radionuclide decay constant, as it
will require modifying the administered dose by more drug
released energy to keep the tumor in its shrinkage pathway as
described in OIDT. It was found that carcinoma as well as
sarcoma risk decreases by applying WEPT or OIDT such that










In such a case, tumor regrowth energy will vanish. Such
an approach, unifying short- and long-term models, has
some advantages over currently existing methods, as
discussed in the previous articles (Moawad 2010; 2011).
Reasons for tumor regrowth are either underestimation or
overestimation of the administered dose. For underestima-
tion, Emad Moawad showed that exposure to certain levels
of radiation of energy less than that of the biological culture
allows harmful nuclear transmutation in biological cultures,
which contributes in their growth and, consequently,
different kinds of cancerous tumors where growth energy
gained is equivalent to energy gained of such elemental
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transmutations (Moawad 2011). While overestimation is the
second reason for tumor regrowth or second cancer, it can
be a reply for several questions like why might secondary
rectal cancer rates be higher in prostate cancer patients who
had conservative treatment (Harlan et al. 2001b). Rajendran
et al. showed the statistical analysis to dose assessment by
ignoring patient-specific factors and using standard models
is responsible for a wide range of doses and, consequently,
second cancer risks (Rajendran et al. 2004). Hence,
significant differences are observed between the tumor
response due to the physical approach and those obtained
from the statistical standard models. This shows that
ignoring patient-specific factors and tumor size that was
handled by WEP and depending on statistical models, lead
to either underestimation or overestimation of the true
tumor energy of individual patients (Fisher 1994). There-
fore, patient-specific approaches that account for variations
in tumor sizes along with its growth doubling time should
enable more accurate dose estimates and, consequently,
better protection against lower or over irradiation that could
lead to tumor growth or serious normal tissue toxicities and
increasing the risks of second cancer.
5 Conclusions
Radiotherapy and its subsequent are an energy balance
process; tumor regrows if its energy is higher than that of
the dose, or if the increase of dose energy from that of the
tumor is less than the required one to complete its shrinkage
path. Patient-specific approaches that account for variations
in tumor energies should enable more accurate dose
estimates and, consequently, better protection against either
lower or over irradiation that could lead to tumor regrowth
and increase risks of second cancer.
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